Compare KMX & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KMX | TNGX |
|---|---|---|
| Founded | 1993 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail-Auto Dealers and Gas Stations | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 4.5B |
| IPO Year | 2002 | 2020 |
| Metric | KMX | TNGX |
|---|---|---|
| Price | $56.07 | $27.72 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 16 | 10 |
| Target Price | ★ $37.18 | $21.78 |
| AVG Volume (30 Days) | 3.5M | ★ 4.5M |
| Earning Date | 04-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.89 |
| EPS | ★ 1.31 | N/A |
| Revenue | ★ $25,881,131,000.00 | $62,384,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.82 | N/A |
| P/E Ratio | $42.68 | ★ N/A |
| Revenue Growth | N/A | ★ 48.29 |
| 52 Week Low | $30.40 | $5.60 |
| 52 Week High | $63.74 | $34.39 |
| Indicator | KMX | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 61.38 | 46.88 |
| Support Level | $39.39 | $19.74 |
| Resistance Level | N/A | $28.41 |
| Average True Range (ATR) | 2.08 | 2.02 |
| MACD | 0.22 | -0.51 |
| Stochastic Oscillator | 56.95 | 9.84 |
CarMax sells, finances, and services used and new cars through a chain of over 250 used retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales were 83% of fiscal 2025 revenue and wholesale about 17%, with the remaining portion composed of extended service plans and repair. In fiscal 2025, the company retailed and wholesaled 789,050 and 544,312 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the US but still estimates that it had only about 3.7% US market share of vehicles 0-10 years old in calendar 2024. It seeks over 5% share. CarMax is based in Richmond, Virginia.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.